The American Journal of Managed Care > May 2014
The American Journal of Managed Care - May 2014
May 20, 2014 – Jinhai Huo, PhD, MD, MPH; David R. Lairson, PhD; Xianglin L. Du, MD, PhD; Wenyaw Chan, PhD; Thomas A. Buchholz, MD; and B. Ashleigh Guadagnolo, MD, MPH
Hospice care is associated with improved median survival time for the patients diagnosed with metastatic melanoma, accompanied by decreased end-of-life costs.
May 20, 2014 – Charles H. Hennekens, MD; Marc A. Pfeffer, MD; John W. Newcomer, MD; Paul S. Jellinger, MD, MACE; and Alan Garber, MD, PhD
The pandemic of type 2 diabetes mellitus requires implementation of multifactorial interventions by clinicians for individual patients and policy makers for the health of the general public.
May 20, 2014 – Clifford Bleustein, MD, MBA; David B. Rothschild, BS; Andrew Valen, MHA; Eduardas Valaitis, PhD; Laura Schweitzer, MS; and Raleigh Jones, MD
Clinic wait times do not just affect overall patient satisfaction, but also specifically affect the perception of providers and the quality of care.
May 20, 2014 – Erica L. Stockbridge, MA; Lindsey M. Philpot, PhD, MPH; and José Pagán, PhD
Analysis of the impact of individual features of the patient-centered medical home care model on future healthcare expenditures among Medicare beneficiaries.
May 21, 2014 – Didem Minbay Bernard, PhD; Patrik Johansson, MD, MPH; and Zhengyi Fang, MS
Among nonelderly adults receiving hypertension treatment, 13.1% had high burdens, meaning that healthcare expenditures accounted for more than 20% of their income.
TRENDS FROM THE FIELD
The SAFER Guides: Empowering Organizations to Improve the Safety and Effectiveness of Electronic Health Records
May 21, 2014 – Dean F. Sittig, PhD; Joan S. Ash, PhD, MLS, MBA; and Hardeep Singh, MD, MPH
We describe the conceptual underpinnings of an EHR-related selfassessment strategy to provide institutions a foundation upon which they can build their safety efforts.
May 19, 2014 – Paul G. Barnett, PhD; Adam Chow, BA; Vilija R. Joyce, MS; Ahmed M. Bayoumi, MD, MSc; Susan C. Griffin, MSc, BSc, PhD; Huiying Sun, PhD; Mark Holodniy, MD; Sheldon T. Brown, MD; D. William Cameron, MD; Mark Sculpher, PhD; Mike Youle, MB, ChB; Aslam H. Anis, PhD; and Douglas K. Owens, MD, MS
Antiretroviral drugs have replaced hospitalization and other services as the most costly component of HIV care, except in patients with especially advanced HIV.
Assessment and Potential Determinants of Compliance and Persistence to Antiosteoporosis Therapy in Italy
May 19, 2014 – Manuela Casula, PhD; Alberico Luigi Catapano, PhD; Rossana Piccinelli, PharmD; Enrica Menditto, PhD; Lamberto Manzoli, MD, MPH; Luisa De Fendi, BSc; Valentina Orlando, PharmD; Maria Elena Flacco, MD; Marco Gambera, PharmD; Alessandro Filippi, MD; and Elena Tragni, PhD
This analysis of antiosteoporosis therapy shows that 75% of patients have inadequate drug coverage and that adherence is strongly associated with age and administration regimen.
Pharmacogenetic-Guided Psychiatric Intervention Associated With Increased Adherence and Cost Savings
May 20, 2014 – Jesen Fagerness, JD; Eileen Fonseca, MS; Gregory P. Hess, MD, MBA, MSc; Rachel Scott, PharmD; Kathryn R. Gardner, MS; Michael Koffler, MBA; Maurizio Fava, MD; Roy H. Perlis, MD, MSc; Francis X. Brennan, PhD; and Jay Lombard, DO
Pharmacy and medical claims data showed that patients whose clinicians had access to pharmacogenetic test results had increased adherence and overall cost savings.
Using Administrative Claims to Identify Children With Chronic Conditions in a Statewide Immunization Registry
May 20, 2014 – Kevin J. Dombkowski, DrPH, MS; Lauren Costello, MSW; Shiming Dong, MS; and Sarah J. Clark, MPH
This study examines the feasibility and utility of using administrative claims from commercial health plans to identify children with chronic conditions in a statewide registry.
May 20, 2014 – Louise H. Anderson, PhD; Robin R. Whitebird, PhD, MSW; Jennifer Schultz, PhD; Charlene E. McEvoy, MD, MPH; Mary Jo Kreitzer, PhD, RN; and Cynthia R. Gross, PhD
Patients with an insomnia diagnosis have higher healthcare utilization and costs than a matched control group, both before and after the diagnosis.